Evidence map›Paper›PMID 39788898›Full record

ArticleMovement disorders : official journal of the Movement Disorder Society2025

TDP-43 Cryptic RNAs in Perry Syndrome: Differences across Brain Regions and TDP-43 Proteinopathies.

Sarah R Pickles, Jesus Gonzalez Bejarano, Anand Narayan, Lillian Daughrity, Candela Maroto Cidfuentes, Madison M Reeves, Mei Yue, Paula Castellanos Otero, Virginia Estades Ayuso, Judy Dunmore and 13 more

Abstract read
In one paragraph

Article in Movement disorders : official journal of the Movement Disorder Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. TDP-43: [GU]-ardian of the transcriptome.Molecular neurodegeneration · 2026
    Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sarah R PicklesDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Jesus Gonzalez BejaranoDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.ORCID https://orcid.org/0009-0006-1677-2760
Anand NarayanDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Lillian DaughrityDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Candela Maroto CidfuentesDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Madison M ReevesDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Mei YueDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Paula Castellanos OteroDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Virginia Estades AyusoDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Judy DunmoreDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Yuping SongDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Jimei TongDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Michael DeTureDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Bailey RawlinsonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Monica Castanedes-CaseyDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Jaroslaw DulskiDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.
Catalina Cerquera-ClevesDepartment of Neurosciences, Neurology Unit, Hospital Universitario San Ignacio, Bogota, Colombia.
Yongjie ZhangDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Keith A JosephsDepartment of Neurology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0003-2930-8634
Dennis W DicksonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Leonard PetrucelliDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, USA.ORCID https://orcid.org/0000-0001-5487-1053
Mercedes PrudencioDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, USA.ORCID https://orcid.org/0000-0002-4894-4858

Funding

Technology and Remote Assessment CoreU19AG063911 · NIA · MAYO CLINIC ROCHESTER · PI KEJAL KANTARCI · 2019 to 2026
$120.9M
TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Research Education ComponentP30AG066514 · NIA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Margaret Sewell · 2020 to 2026
$31.0M
Project 3: Neuropathology of the multi-proteinopathy of c9FTD/ALS.P01NS084974 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2014 to 2024
$17.6M
Expanding insights into FTD disease mechanismsR35NS097273 · NINDS · MAYO CLINIC JACKSONVILLE · PI PETRUCELLI, LEONARD · 2017 to 2024
$10.6M
Human Biomarkers CoreU54NS123743 · NINDS · STANFORD UNIVERSITY · PI FRATTA, PIETRO, GITLER, AARON D. · 2021 to 2025
$8.2M
Understanding the role of TDP-43 in Alzheimers disease and FTLDR01AG037491 · NIA · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A · 2010 to 2024
$6.5M
Stathmin-2 and TDP-43 neurodegeneration in Alzheimer’s and multi-etiology dementiasRF1NS120992 · NINDS · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Keith A Josephs, Mercedes Prudencio · 2021 to 2026
$4.2M
Stathmin-2 and TDP-43 neurodegeneration in Alzheimer’s and multi-etiology dementiasR01NS120992 · NINDS · MAYO CLINIC ROCHESTER · PI JOSEPHS, KEITH A, PRUDENCIO, MERCEDES · 2024 to 2025
$1.6M
BrightFocus FoundationHaworth Family Professorship in Neurodegenerative Diseases fund 90052067Margaret N. and John Wilchek FamilyNIA NIH HHS P01 AG019724NIA NIH HHS P30 AG066514NIA NIH HHS R01 AG037491NIA NIH HHS U19 AG063911NIH HHS R01AG037491NIH HHS R35NS097273NIH HHS RF1NS120992NIH HHS U19AG063911NIH HHS U54NS123743NINDS NIH HHS P01 NS084974NINDS NIH HHS R01 NS120992NINDS NIH HHS R35 NS097273NINDS NIH HHS RF1 NS120992NINDS NIH HHS U54 NS123743PPND Family FoundationRobert Packard Center for ALS Research at Johns HopkinsTarget ALSThe Albertson Parkinson's Research FoundationVanier Canada Graduate Scholarship from the Canadian Institutes of Health Research
6 · The paper itself

Abstract

backgroundPerry syndrome (PS) is a rare and fatal hereditary autosomal dominant neurodegenerative disorder caused by mutations in dynactin (DCTN1). PS brains accumulate inclusions positive for ubiquitin, transactive-response DNA-binding protein of 43 kDa (TDP-43), and to a lesser extent dynactin.

objectivesLittle is known regarding the contributions of TDP-43, an RNA binding protein that represses cryptic exon inclusion, in PS. Therefore, we sought to identify the degree of TDP-43 dysfunction in two regions of PS brains.

methodsWe evaluated the levels of insoluble pTDP-43 and TDP-43-regulated cryptic RNAs and protein in the caudate nucleus and substantia nigra of 7 PS cases, 12 cases of frontotemporal lobar degeneration (FTLD) with TDP-43 pathology, and 11 cognitively healthy controls without TDP-43 pathology.

resultsInsoluble pTDP-43 protein levels were detected in PS brains to a similar extent in the caudate nucleus and substantia nigra but lower than those in FTLD brains. The caudate nucleus of PS showed accumulation of eight TDP-43-regulated cryptic RNAs (ACTL6B, CAMK2B, STMN2, UNC13A, KCNQ2, ATG4B, GPSM2, and HDGFL2) and cryptic protein (HDGFL2) characteristic of FTLD. Conversely, only one cryptic target, UNC13A, reached significance in the substantia nigra despite similar pTDP-43 levels.

conclusionWe detected TDP-43 cryptic RNAs and protein in PS caudate nucleus. Given the importance of cryptic exon biology in the development of biomarkers, and the identification of novel targets for therapeutic intervention, it is imperative we understand the consequences of TDP-43 dysfunction across different brain regions and determine the targets that are specific and common to TDP-43 proteinopathies. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Indexed as

BrainCaudate NucleusDNA-Binding ProteinsParkinsonian DisordersSubstantia NigraTDP-43 ProteinopathiesAgedAged, 80 and overDepressionDynactin ComplexFemaleFrontotemporal Lobar DegenerationHumansHypoventilationMaleMiddle AgedDCTN1 protein, humanDNA-Binding ProteinsDynactin ComplexTARDBP protein, humancrypticfrontotemporal dementiafrontotemporal lobar degenerationPerry syndrometransactive‐response DNA‐binding protein of 43 kDa (TDP‐43)

Identifiers

PMID39788898
PMCPMC12006891

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.